Keytruda Unlocked: How Should Merck Proceed with Trials?

As a blockbuster drug raking in nearly $21 billion in 2022 alone, Keytruda (pembrolizumab) has a reputation for being omnipresent in cancer therapy discussions worldwide.

As a cancer agent, Keytruda operates by binding to the PD-1 receptor on T-cells regardless of whether these are tumor cells or healthy cells, to serve as a checkpoint inhibitor.